Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289533 | 0.75 | GCGR (0.43) | ALDH1A1SMN1; SMN2NPC1EPHX2KMT2A | |
| SCHEMBL2646748 | 0.61 | GCGR (0.47) | ALDH1A1CYP2C19SMN1; SMN2NPC1EPHX2 | |
| SCHEMBL19048543 | 0.61 | PTGS2 (0.51) | ALDH1A1ALOX5APFEN1SMN1; SMN2NPC1 | |
| SCHEMBL18459668 | 0.61 | SMN1; SMN2 (0.52) | ALDH1A1CYP2C19SMN1; SMN2NPC1EPHX2 | |
| SCHEMBL3912459 | 0.60 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C19ALOX5APFEN1 | |
| SCHEMBL11467456 | 0.60 | PTGDR2 (0.43) | KMT2AMEN1TSHR | |
| SCHEMBL4946893 | 0.59 | SMN1; SMN2 (0.50) | ALDH1A1CYP2C19SMN1; SMN2NPC1EPHX2 | |
| SCHEMBL1793340 | 0.59 | KDM4E (0.54) | ALDH1A1SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL2944396 | 0.59 | ALDH1A1 (0.59) | ALDH1A1CYP2C19SMN1; SMN2NPC1EPHX2 | |
| SCHEMBL1790000 | 0.59 | ALDH1A1 (0.59) | ALDH1A1CYP2C19SMN1; SMN2NPC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ALDH1A1 4046/4885CYP3A4 2800/4885CYP2C19 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.